EXOM, is a globally acting full-service CRO (Contract Research Organization), founded in 2014 in Milan (Italy). Exom’s primary mission is to implement next-generation clinical trial 5.0 processes by exploiting innovative technologies and combining them with our...
Digital technologies have been used in clinical studies for years. So far, however, they have been used very hesitantly by sponsors, study centers and CROs. Authorities have also been very hesitant to approve their use. The Covid-19 pandemic, however, has changed this...
In the aftermath of the Covid-19 pandemic, there was a debate both on the limits of typical on-site monitoring visits and on whether alternative technology-based solutions should continue to be used, even under normal conditions. As known during the pandemic, the...
Exom Group Srl, in collaboration with Meteda Srl, announces the release of Genius FIRE Diabetes, the first large-scale eSource infrastructure operating in Europe for more efficient conduction of Clinical Trials in Diabetes. As is well known, Diabetes is one of the...
Crises are rare periods in history when need stimulates the search for innovative solutions and accelerates the timing to start adopting them. Given the enormous investments that the life sciences industry makes in drug development, it is not surprising that...
Although industry 4.0 has so far been the most advanced of all industrial revolutions, it is in no way the last frontier. Industry 5.0 is already on the horizon. Below you will see how it will impact clinical research. The risk of infection and the difficulties in...
Exom is proud to announce that Corporate Vision Magazine has awarded us the 2021 Corporate Excellence Award as "Most innovative Full-Service CRO" for our technology-driven approach to clinical trial management.
